Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA ALLERGY versus CLARITIN D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALLEGRA ALLERGY versus CLARITIN D.
CHILDREN'S ALLEGRA ALLERGY vs CLARITIN-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
Fexofenadine 60 mg orally twice daily or 180 mg once daily.
One tablet (5 mg loratadine/120 mg pseudoephedrine sulfate) orally every 12 hours; do not exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours) in healthy adults. In children aged 6–12 years, half-life is similar. Clinical context: allows once-daily dosing.
Loratadine: 8-14 h (mean 11 h); desloratadine: 17-24 h (mean 21 h). Pseudoephedrine: 4-8 h (mean 6 h), prolonged in alkaline urine.
Fexofenadine is excreted primarily unchanged in feces (approximately 80%) and urine (approximately 11%). Biliary excretion accounts for a minor portion.
Loratadine: 40% renal (metabolites), ~40% fecal; desloratadine: 33% renal, 66% fecal. Pseudoephedrine: 70-90% renal unchanged, 1-2% biliary.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination